Abstract
The first compounds showing efficacy in the treatment of schizophrenia and other psychotic disorders was chlorpromazine, an anti-histaminic compound casually observed to possess antipsychotic effects. The discovery of the real mechanism of action of antipsychotic substances dates back to the 1960s, when researchers found that these compounds act as dopamine receptor antagonists. Unfortunately, this type of drugs cannot block the D2 receptors only in the mesolimbic dopaminergic pathway (which mediates their therapeutic effects), because of their non-selective D2 receptor blockage in both the mesolimbic and striatal regions, and the consequent appearance of side effects related to striatal interaction in the same dosage range as is needed for the therapeutical effects. Clozapine, discovered in the early 1970s, seemed to represent the solution to contrast these side effects, as it possesses antipsychotic activity without inducing extrapyramidal disorders in humans or catalepsy in rats; for this reason, it was defined as an “atypical” antipsychotic drug. Later, other beneficial properties, such as improvement of negative symptoms and of cognitive dysfunction and efficacy in neurolepticresistant schizophrenia, were included in the definition of “atypical”. In recent years, the appearance of new atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone) has opened new ways to therapy. The aim of this paper is to review literature about newer antipsychotics, focusing on their advantages in terms of efficacy and side effect profiles when compared to classical and older atypical antipsychotics, and to evaluate the efficacy of the different new antipsychotics when compared to one another.
Keywords: schizophrenia, antipsychotics, review, atypical
Current Medicinal Chemistry
Title: New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Volume: 11 Issue: 3
Author(s): Alessandro Serretti, Diana De Ronchi, Cristina Lorenzi and Domenico Berardi
Affiliation:
Keywords: schizophrenia, antipsychotics, review, atypical
Abstract: The first compounds showing efficacy in the treatment of schizophrenia and other psychotic disorders was chlorpromazine, an anti-histaminic compound casually observed to possess antipsychotic effects. The discovery of the real mechanism of action of antipsychotic substances dates back to the 1960s, when researchers found that these compounds act as dopamine receptor antagonists. Unfortunately, this type of drugs cannot block the D2 receptors only in the mesolimbic dopaminergic pathway (which mediates their therapeutic effects), because of their non-selective D2 receptor blockage in both the mesolimbic and striatal regions, and the consequent appearance of side effects related to striatal interaction in the same dosage range as is needed for the therapeutical effects. Clozapine, discovered in the early 1970s, seemed to represent the solution to contrast these side effects, as it possesses antipsychotic activity without inducing extrapyramidal disorders in humans or catalepsy in rats; for this reason, it was defined as an “atypical” antipsychotic drug. Later, other beneficial properties, such as improvement of negative symptoms and of cognitive dysfunction and efficacy in neurolepticresistant schizophrenia, were included in the definition of “atypical”. In recent years, the appearance of new atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone) has opened new ways to therapy. The aim of this paper is to review literature about newer antipsychotics, focusing on their advantages in terms of efficacy and side effect profiles when compared to classical and older atypical antipsychotics, and to evaluate the efficacy of the different new antipsychotics when compared to one another.
Export Options
About this article
Cite this article as:
Serretti Alessandro, Ronchi De Diana, Lorenzi Cristina and Berardi Domenico, New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects, Current Medicinal Chemistry 2004; 11 (3) . https://dx.doi.org/10.2174/0929867043456043
DOI https://dx.doi.org/10.2174/0929867043456043 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual COX-Inhibitors: The Answer is NO?
Current Topics in Medicinal Chemistry Prevention of Contrast Induced Nephropathy
Current Drug Therapy Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery
Current Drug Metabolism Comparison of Status Epilepticus Models Induced by Pilocarpine and Nerve Agents - A Systematic Review of the Underlying Aetiology and Adopted Therapeutic Approaches
Current Medicinal Chemistry Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Enantioselective Transfer Reaction of Phenyl to Aldehydes Using LProline- Derived Amino Alcohols as Chiral Ligands
Letters in Organic Chemistry Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Orthostatic Hypotension: Evaluation and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Inhibition of Endotoxin Response by Synthetic TLR4 Antagonists
Current Topics in Medicinal Chemistry Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology CRF Receptor Antagonists: Utility in Research and Clinical Practice
Current Medicinal Chemistry The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Lipid Nanocarriers (LNC) and their Applications in Ocular Drug Delivery
Current Medicinal Chemistry